Lineage Cell Therapeutics Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Lineage Cell Therapeutics, Inc. (LCTX) filed its Q1 2024 10-Q report on May 9, 2024, detailing financial performance and business operations.</b>

AI Summary

Lineage Cell Therapeutics, Inc. (LCTX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Lineage Cell Therapeutics, Inc. filed a 10-Q report for the period ending March 31, 2024. The filing covers the first quarter of fiscal year 2024. Key dates mentioned include 2024-03-31 for financial reporting and 2024-05-09 as the filing date. The company's principal business is in Biological Products (No Diagnostic Substances) under SIC code 2836. The filing references various agreements and plans, including the Roche Agreement and the 2021 Equity Incentive Plan.

Why It Matters

For investors and stakeholders tracking Lineage Cell Therapeutics, Inc., this filing contains several important signals. This 10-Q filing provides investors with the latest quarterly financial results and operational updates for Lineage Cell Therapeutics, crucial for assessing the company's performance and future prospects. Understanding the details within this report, such as revenue segments, expenses, and any new agreements or risks, is essential for making informed investment decisions regarding LCTX.

Risk Assessment

Risk Level: medium — Lineage Cell Therapeutics, Inc. shows moderate risk based on this filing. The company operates in the biotechnology sector, which is inherently risky due to long development cycles, regulatory hurdles, and high R&D costs, as indicated by the mention of research and development expenses.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-Q to assess the company's current financial health and future growth potential.

Key Numbers

• 2024-03-31 — Reporting Period End Date (Conformed Period of Report)
• 2024-05-09 — Filing Date (Filed as of date)
• 2836 — SIC Code (Standard Industrial Classification)
• 2024-01-01 — Start of Q1 2024 (Fiscal period reference)

Key Players & Entities

• Lineage Cell Therapeutics, Inc. (company) — Filer name
• LCTX (company) — Ticker symbol
• 2024-03-31 (date) — Conformed period of report
• 2024-05-09 (date) — Filed as of date
• 2836 (industry_code) — Standard Industrial Classification
• Roche Agreement (contract) — Mentioned agreement
• Hadasit Medical Research Services and Development Ltd (company) — Mentioned entity in agreement context
• Neal Bradsher (person) — Mentioned individual

FAQ

Risk Factors

• Financial Position and Liquidity [medium — financial]: The company's financial statements and disclosures provide insights into its assets, liabilities, and cash flows, which are critical for assessing its ability to fund operations and future growth.
• Biotechnology Sector Regulations [high — regulatory]: Operating in the biotechnology sector subjects the company to stringent regulatory oversight and lengthy approval processes for its products, impacting development timelines and market access.
• Research and Development Expenses [medium — operational]: Significant investment in research and development is a characteristic of the biotechnology industry, posing financial risks if R&D efforts do not yield successful commercial products.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
• 2024-05-09: Filing Date — Date the 10-Q report was officially submitted to the SEC.

Filing Documents

• lctx-20240331.htm (10-Q) — 1576KB
• lctx-ex10_1.htm (EX-10.1) — 18KB
• lctx-ex10_2.htm (EX-10.2) — 18KB
• lctx-ex10_3.htm (EX-10.3) — 18KB
• lctx-ex31_1.htm (EX-31.1) — 13KB
• lctx-ex31_2.htm (EX-31.2) — 12KB
• lctx-ex32_1.htm (EX-32.1) — 9KB
• 0000950170-24-056998.txt (&nbsp;) — 7868KB
• lctx-20240331.xsd (EX-101.SCH) — 1261KB
• lctx-20240331_htm.xml (XML) — 1305KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Comprehensive Loss 7 Condensed Consolidated Statements of Changes in Shareholders' Equity 8 Condensed Consolidated Statements of Cash Flows 9 Notes to the Condensed Consolidated Interim Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Result of Operations

Management's Discussion and Analysis of Financial Condition and Result of Operations 27 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 34 Item 4.

Controls and Procedures

Controls and Procedures 34 PART II. OTHER INFORMATION 35 Item 1.

Legal Proceedings

Legal Proceedings 35 Item 1A.

Risk Factors

Risk Factors 35 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 35 Item 3. Defaults Upon Senior Securities 35 Item 4. Mine Safety Disclosures 35 Item 5. Other Information 35 Item 6. Exhibits 36

Signatures

Signatures 37 2 SPECI AL NOTE REGARDING FORWARD-LOOKING STATEMENTS This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations" of this report, but are also contained elsewhere in this report. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this report are forward-looking statements. In some cases, you can identify forward-looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements in this report include, but are not limited to, statements about: the potential to receive developmental, regulatory, and commercialization milestone and royalty payments under our Collaboration and License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc.; our plans to research, develop and commercialize our product candidates; the initiation, progress, success, cost and timing of our clinical trials and other product development activities; the therapeutic potential of our product candidates, and the indications for which we intend to develop our product candidates; our ability to successfully manufacture our product candidates for clinical development and, if approved, for commercialization, and the timing and c

View Full Filing

View this 10-Q filing on SEC EDGAR